# Effect of Peri-operative anti-HER2 therapy On early breast cancer Study - Biological phase

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
23/02/2009		[X] Protocol		
Registration date 19/03/2009	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	[] Individual participant data		
21/12/2023	Cancer			

## Plain English summary of protocol

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-effect-having-trastuzumab-or-lapatinib-before-surgery-early-breast-cancer-ephos-b

#### Study website

https://www.icr.ac.uk/our-research/centres-and-collaborations/centres-at-the-icr/clinical-trials-and-statistics-unit/our-research/clinical-trials

# Contact information

# Type(s)

Scientific

#### Contact name

**Prof Nigel Bundred** 

#### Contact details

University of Manchester c/o University of South Manchester NHS Foundation Trust 2nd Floor, Education and Research Centre Southmoor Road Manchester United Kingdom M23 9LT

bundred@manchester.ac.uk

# Type(s)

Public

#### Contact name

Ms Jane Banerji

#### Contact details

ICR-CTSU
Sir Richard Doll Building
Institue of Cancer Research
Cotswold Road
Sutton
United Kingdom
SM2 5NG
+44(0)0208 722 4349
EPHOS-B-icrctsu@icr.ac.uk

# Additional identifiers

# **EudraCT/CTIS** number

2008-005466-30

#### IRAS number

6930

#### ClinicalTrials.gov number

NCT01104571

#### Secondary identifying numbers

ICR-CTSU/2008/10017, IRAS 6930

# Study information

#### Scientific Title

Effect of peri-operative anti-HER2 therapy on early breast cancer: a randomised phase III open-label multicentre clinical trial

#### **Acronym**

**EPHOS-B** 

# **Study objectives**

The EPHOS-B study will test the hypothesis that peri-operative anti-HER2 therapy causes a significant increase in tumour apoptosis and a significant decrease in tumour cell proliferation.

Please note that as of 19/02/10 this record has been updated. All updates can be found in the relevant field with the above update date. Please also note that the start and end dates of this trial have been updated from 01/06/2009 and 01/12/2009 to 01/04/2010 and 01/11/2021 respectively. This includes the follow up period.

# Ethics approval required

Ethics approval required

# Ethics approval(s)

Approved 12/01/2010, West Midlands Research Ethics Committee (1st Floor, NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle Upon Tyne, NE2 4NQ, United Kingdom; +44 (0) 2071048357; edgbaston.rec@hra.nhs.uk), ref: 09/H1208/52

#### Study design

Randomized phase III open-label multicentre clinical trial

# Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

#### Study setting(s)

Hospital

#### Study type(s)

Treatment

#### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

#### Health condition(s) or problem(s) studied

Early breast cancer

#### **Interventions**

Current information as of 19/02/10:

Group I: control (i.e. no peri-operative treatment)

Group II: trastuzumab 6 mg/kg intravenous (iv) given on days 1 and 8 pre-surgery, and 2 mg/kg iv on day 15 post-operatively

Group III: Lapatinib 1500mg/day p.o. continuously for 28 days, starting 11 days (± 1 day) presurgery.

Initial information at time of registration:

Group I: control (i.e. no peri-operative treatment)

Group II: trastuzumab 6 mg/kg intravenous (iv) given on days 1 and 8 pre-surgery, and 2 mg/kg iv on days 15 and 22 post-operatively

Group III: lapatinib 1500 mg/day orally (p.o.) for approximately 6 weeks, starting 11 days ( $\pm$  1 day) pre-operatively and continued for 4 weeks post-operatively

Patients should be followed-up 28 days after surgery and then every 6 months until the end of year 2. Patients will then be followed up annually for at least 10 years after completion of recruitment.

#### Joint sponsors:

University Hospital of South Manchester NHS Foundation Trust (UK)
2nd Floor, Education and Research Centre
Southmoor Road
Manchester M23 9LT
United Kingdom
Email: Bundred@manchester.ac.uk
http://www.uhsm.nhs.uk/Pages/Home.aspx

Institute of Cancer Research (ICR) (UK) 123 Old Brompton Road London SW7 3PR

Tel: +44 (0)20 8722 4188 Fax: +44 (0)20 8770 7876

Email: Barbara.Pittam@icr.ac.uk

http://www.icr.ac.uk

#### Intervention Type

Drug

#### Phase

Phase III

#### Drug/device/biological/vaccine name(s)

Trastuzumab, lapatinib

#### Primary outcome measure

- 1. Increase in apoptosis: change in the tumour (morphological apoptosis and activated caspase 3) measured at diagnosis and at surgery
- 2. Fall in proliferation between diagnosis and surgery: change in proliferation measured by Ki67 immunohistochemical assessment (%) at diagnosis and at surgery

#### Secondary outcome measures

- 1. Changes in the angiogenic serum markers vascular endothelial growth factor A (VEGF-A), VEGF-R1 and CD105, measured at diagnosis, surgery (plus also tumour CD31) and 28 days post-surgery
- 2. To establish if the expression of molecular markers (epidermal growth factor receptor [EGFR], Her-3, insulin-like growth factor 1 receptor [IGF1R], c-myc, Akt, p-ERK, pS6 Kinase, activated Src, or truncated p95HER-2 expression) predict increases in apoptosis or decreases in proliferation in response to therapy

#### Overall study start date

01/04/2010

## Completion date

19/12/2022

# Eligibility

#### Key inclusion criteria

- 1. Women aged greater than or equal to 18 years old
- 2. HER2 (3+ on immunohistochemistry [IHC] or amplification proven by fluorescent in-situ hybridisation [FISH]) positive operable invasive breast cancer diagnosed by core biopsy
- 3. Planned surgery within one month of diagnosis
- 4. Serum creatinine and bilirubin less than 2 times the upper limits of normal for the institution, or creatinine clearance greater than 30 mg/dL (Marginally abnormal test results should be repeated)
- 5. Eastern Cooperative Oncology Group (ECOG) performance status 0,1, or 2 (Karnofsky greater than or equal to 60%)

- 6. Non-pregnant and non-lactating with no intention of pregnancy during study treatment
- 7. Written informed consent obtained for trial and to donation of tissue and blood samples

#### Added 19/02/10:

8. Patients must be candidates for and willing to undergo adjuvant chemotherapy and trastuzumab post surgery

#### Participant type(s)

**Patient** 

#### Age group

Adult

#### Lower age limit

18 Years

#### Sex

Female

# Target number of participants

250

#### Total final enrolment

257

## Key exclusion criteria

Current information as of 19/02/10:

- 1. HER2 negative cancers and those with unknown HER2 status
- 2. Inoperable breast cancer (T4 category) or suspicion of distant metastases
- 3. Diagnosis of inflammatory breast cancer
- 4. Clinical evidence of metastatic disease
- 5. Prior herceptin therapy within the last 3 months or local (radiotherapy) cancer treatments
- 6. Previous cancer at any other site that has been treated within the last 6 months (except previous basal cell carcinoma and cervical carcinoma in situ)
- 7. Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
- 8. Impaired gastro-intestinal function thought sufficient to reduce lapatinib absorption
- 9. Contra-indicated to receive adjuvant chemotherapy and/or trastuzumab (ECOG >2)
- 10. Known immediate or delayed hypersensitivity, reaction to drugs chemically related to trastuzumab or lapatinib
- 11. Other concomitant investigational agents or concurrent anti-cancer therapy
- 12. Regular use of systemic steroids or other agents that could influence study endpoints (inhaled steroids are allowed)
- 13. Any altered mental state that would preclude obtaining written informed consent
- 14. Patients who have clinically significant cardiac abnormalities or uncontrolled hypertension
- 15. Previous myocardial infarction, heart failure, or significant angina. Cardiac function should be assessed by physical examination, ECG, and baseline LVEF should be ≥55% as measured by echocardiography or MUGA.

Initial information at time of registration:

- 1. HER2 negative cancers and those with unknown HER2 status
- 2. Inoperable breast cancer (T4 category) or suspicion of distant metastases
- 3. Diagnosis of inflammatory breast cancer
- 4. Clinical evidence of metastatic disease
- 5. No prior systemic (i.e. chemotherapy) or local (radiotherapy) cancer treatments
- 6. Previous cancer at any other site (except previous basal cell carcinoma and cervical carcinoma in situ)
- 7. Abnormal renal function
- 8. Abnormal liver function tests
- 9. Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
- 10. Impaired gastro-intestinal function thought sufficient to reduce lapatinib absorption
- 11. Contra-indication to receive adjuvant chemotherapy and/or trastuzumab (ECOG greater than 2)
- 12. Known immediate or delayed hypersensitivity, reaction to drugs chemically related to trastuzumab or lapatinib
- 13. Other concomitant investigational agents or concurrent anti-cancer therapy. In addition all herbal (alternative) therapies are prohibited.
- 14. Regular use of systemic steroids or other agents that could influence study endpoints
- 15. Patient must not have clinically significant cardiac abnormalities or uncontrolled hypertension
- 16. No previous myocardial infarction, heart failure, or significant angina. Cardiac function should be assessed by physical examination, electrocardiogram (ECG), and baseline left ventricular ejection fraction (LVEF) should be greater than or equal to 50% as measured by echocardiography or multiple-gated acquisition (MUGA) scan.

Date of first enrolment

01/04/2010

Date of final enrolment 30/09/2015

# Locations

Countries of recruitment

England

United Kingdom

Study participating centre
University of Manchester
Manchester
United Kingdom
M23 9LT

# Sponsor information

#### Organisation

University of Manchester (UK)

#### Sponsor details

Oxford Road Manchester England United Kingdom M13 9PL

#### Sponsor type

University/education

#### Website

http://www.manchester.ac.uk

#### **ROR**

https://ror.org/027m9bs27

# Funder(s)

# Funder type

Charity

#### **Funder Name**

Cancer Research UK (CRUK) (UK) (ref: C7525/A8965)

# Alternative Name(s)

CR\_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

# Funding Body Type

Private sector organisation

# **Funding Body Subtype**

Other non-profit organizations

#### Location

United Kingdom

#### **Funder Name**

GlaxoSmithKline (UK)

#### Alternative Name(s)

GlaxoSmithKline plc., GSK plc., GlaxoSmithKline plc, GSK

#### **Funding Body Type**

Government organisation

#### **Funding Body Subtype**

For-profit companies (industry)

#### Location

**United Kingdom** 

# **Results and Publications**

# Publication and dissemination plan

Has been presented at international conferences and published in Clinical Cancer Research April 2022

# Intention to publish date

01/12/2019

#### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

EPHOS-B-icrctsu@icr.ac.uk

#### IPD sharing plan summary

Available on request

#### **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Abstract results		01/03/2016	09/03/2023	No	No
Poster results	version 2	07/12/2021	09/03/2023	No	No
Results article		01/04/2022	09/03/2023	Yes	No
HRA research summary			28/06/2023	No	No
Plain English results			17/07/2023	No	Yes
Protocol file	version 8.0	04/09/2019	21/12/2023	No	No